Belgian and US Biotechs Team up to Reduce CAR T Side Effects
The diagnostics company Biocartis is collaborating with Kite Pharma to monitor the progress of CAR…
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportThe diagnostics company Biocartis is collaborating with Kite Pharma to monitor the progress of CAR…
In biotechnology, plasmids are commonly used as vectors for the replication and cloning of recombinant…
Cell Medica’s next-generation CAR-T cell therapy has resulted in 'extensive tumor regression' in a…
The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention…
With this year coming to a close, it’s now time to look back at the…
As 2018 draws to a close and our thoughts are torn between holiday plans and…
A new CAR-T cancer therapy from the Belgian company Celyad has shown early positive results…
Update: Following on from earlier approvals in the US, the European Commission announced it has given…
Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent…
Kite will support Gadeta in the development of a new type of CAR-T therapy that…
London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a…
Cellectis is developing a new type of chimeric antigen receptor that could improve the production…